Pegfilgrastim use during chemotherapy: current and future applications

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Chemotherapy-induced myelosuppression, particularly neutropenia, is a significant dose-limiting side effect of cancer treatment.
• Neutropenia increases risks of infection, hospitalization, and mortality, potentially leading to chemotherapy dose delays or reductions, impacting patient survival.
• Granulocyte colony-stimulating factors (G-CSF) mitigate neutropenia, enabling planned chemotherapy administration.

Purpose of the Study:

• To review recent clinical trial data on pegfilgrastim, a modified G-CSF with a longer half-life.
• To evaluate the safety and efficacy of once-per-cycle pegfilgrastim compared to daily filgrastim.
• To explore novel applications of pegfilgrastim in managing chemotherapy-induced neutropenia.

Main Methods:

• Clinical trials involving myelosuppressive chemotherapy in breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
• Assessment of pegfilgrastim's safety and efficacy in reducing the duration of severe neutropenia.
• Comparison of pegfilgrastim's outcomes with those of filgrastim.

Main Results:

• Pegfilgrastim demonstrated comparable safety and efficacy to filgrastim in decreasing severe neutropenia duration post-chemotherapy.
• Once-per-cycle pegfilgrastim administration was evaluated in various nonmyeloid malignancies.
• The extended half-life of pegfilgrastim allows for less frequent dosing compared to filgrastim.

Conclusions:

• Pegfilgrastim is a safe and effective option for preventing and treating chemotherapy-induced neutropenia (CIN).
• Its convenient dosing schedule supports adherence and facilitates consistent chemotherapy delivery.
• Pegfilgrastim represents an advancement in supportive care for cancer patients undergoing myelosuppressive chemotherapy.